| Date | Title | Description |
| 24.09.2024 | Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma | London, UK and Bristol, UK, 24 September 2024 –Quell Therapeutics Ltd (“Quell” or “the Company”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and eXm... |
| 10.07.2024 | Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors | London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Beshar a... |
| 09.06.2023 | Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases | London, UK – June 9 2023 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system today announced that it has entered into a collabor... |
| 21.11.2022 | Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer | Adds significant clinical, translational science and immunology expertise to leadership team as Quell prepares to advance QEL-001 into its first clinical trial and progresses its CAR-Treg cell therapy pipeline programs in Auto-Immunity and ... |
| 30.11.2021 | Quell Therapeutics raises $156 million in oversubscribed Series B financing | |
| 30.11.2021 | London's Quell Therapeutics lands $156M | Biotech startup Quell Therapeutics has secured a $156 million Series B. The round was led by Jeito Capital, Ridgeback Capital, SV Health Investors and Fidelity Management & Research. Quell, which develops cell therapies for autoimmune a... |
| 29.11.2021 | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the imm... |
| 29.11.2021 | Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M round | Fierce 15 winner Quell Therapeutics has nabbed a huge $156 million series B round for its new-look cell therapy work.
Sponsored by IPM.AI Whitepaper: Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and R... |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 29.11.2021 | Axie Infinity is a sexy new blockchain-based model of gaming—but it’s facing the same old crypto pitfalls | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Hello Term Sheet readers, from my flight some 36,000 feet up in the air en route to San Francisco... |
| 29.11.2021 | Quell Therapeutics Raises $156M in Series B Financing | Quell Therapeutics Ltd, a London, UK and Boston, MA-based leader in the development of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, raised $156m in a Series B financing.
The round... |
| 29.11.2021 | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the imm... |
| 29.11.2021 | Jeito Capital Co-Leads $156 Million Oversubscribed Series B Financing In Quell Therapeutics | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the imm... |
| 29.11.2021 | Next-gen CAR player Quell Therapeutics drives into the fast lane with major $156M round | Fierce 15 winner Quell Therapeutics has nabbed a huge $156 million series B round for its new-look cell therapy work.
The London- and Boston-based biotech will funnel some of the cash into its lead asset, QEL-100, for human trials, making i... |
| 29.11.2021 | Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 29.11.2021 | Cell therapy biotech Quell adds $156M for alternative to organ transplant meds | Organ transplants require drugs that reduce the chances of the body rejecting a donor organ, but these immuno-suppressive therapies also raise the risk of infection. That risk is ongoing as anti-rejection therapies must be taken for life. Q... |
| 27.10.2021 | Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy | First clinical trial will investigate QEL-001 as a novel treatment to prevent organ rejection in liver transplant patients and eliminate the need for lifelong systemic immunosuppression
Quell Therapeutics Ltd ("Quell"), the world ... |
| 22.07.2021 | Syncona : Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer | Dr. Hartl, former Therapeutic Area Head - Autoimmunity/Transplantation/Inflammation at Novartis Institutes for Biomedical Research (NIBR), to lead Quell's innovative multi-modular Treg cell therapy programs into clinical development
Quell T... |
| 15.02.2021 | London biotech Quell Therapeutics raises a total of £60.4M in Series A, largest in Treg field | Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, recently announced the closing of an extended Series A.
The financing round was led by their existing investors Syncona Ltd ... |
| 11.02.2021 | Quell Therapeutics Expands Series A Financing to $84 Million | |
| 07.01.2021 | Biggest winners, brightest futures: 10 young tech startups from UK ready to own 2021 | Want to know which newly-founded tech startup from UK gained maximum popularity in 2020? Or raised the maximum funding? Which one has the most eminent future?
Many startups that stepped into the gap of legacy companies have been scaleups: f... |
| 20.05.2019 | Quell Therapeutics Raises $35M in Series A Funding | Quell Therapeutics, a London, UK-based cell therapy company, raised $35m in Series A funding.
The round was led by Syncona (£34.0m) with participation from UCL Technology Fund (£1.0m).
Syncona will have a 69.3% stake in the business, with t... |
| 20.05.2019 | UCLTF completes £1m investment into Quell Therapeutics as part of £35m Series A round | Syncona announces the foundation of Quell Therapeutics, a new cell therapy company, with a £35 million commitment in a Series A financing of which Syncona has committed £34 million with a further £1 million being contributed by UCL Technolo... |
| - | Cell therapy has revolutionized cancer treatment. Now the California biotech Sangamo is trying to see if it can also upend autoimmune diseases. | Scientists in the lab at Sangamo Therapeutics. Sangamo Therapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
California biotech Sangamo Therapeutics has given its first doses of an... |
| - | Cell therapy biotech Quell adds $156M for alternative to organ transplant meds | Organ transplants require drugs that reduce the chances of the body rejecting a donor organ, but these immuno-suppressive therapies also raise the risk of infection. That risk is ongoing as anti-rejection therapies must be taken for life. Q... |
